 | Up a level |
Van Emmenis, Lucie; Ku, Sheng-Yu; Gayvert, Kaitlyn; Branch, Jonathan R; Brady, Nicholas J; Basu, Subhasree; Russell, Michael; Cyrta, Joanna; Vosoughi, Aram; Sailer, Verena; Alnajar, Hussein; Dardenne, Etienne; Koumis, Elena; Puca, Loredana; Robinson, Brian D; Feldkamp, Michael D; Winkis, Annmarie; Majewski, Nathan; Rupnow, Brent; Gottardis, Marco M; ... (2023). The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer. Cancer research communications, 3(8), pp. 1447-1459. American Association for Cancer Research 10.1158/2767-9764.CRC-22-0491
Sugita, Mayumi; Wilkes, David C; Bareja, Rohan; Eng, Kenneth W; Nataraj, Sarah; Jimenez-Flores, Reyna A; Yan, LunBiao; De Leon, Jeanne Pauline; Croyle, Jaclyn A; Kaner, Justin; Merugu, Swathi; Sharma, Sahil; MacDonald, Theresa Y; Noorzad, Zohal; Panchal, Palak; Pancirer, Danielle; Cheng, Shuhua; Xiang, Jenny Z; Olson, Luke; Van Besien, Koen; ... (2021). Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ precision oncology, 5(1), p. 44. Springer Nature 10.1038/s41698-021-00183-2
Lee, Rachel S; Zhang, Luxi; Berger, Adeline; Lawrence, Mitchell G; Song, Jiangning; Niranjan, Birunthi; Davies, Rebecca G; Lister, Natalie L; Sandhu, Shahneen K; Rubin, Mark A.; Risbridger, Gail P; Taylor, Renea A; Rickman, David S; Horvath, Lisa G; Daly, Roger J (2019). Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. Neoplasia, 21(4), pp. 389-400. Elsevier 10.1016/j.neo.2019.02.005
Beltran, Himisha; Oromendia, Clara; Danila, Daniel C; Montgomery, Bruce; Hoimes, Christopher; Szmulewitz, Russell Z; Vaishampayan, Ulka; Armstrong, Andrew J; Stein, Mark; Pinski, Jacek; Mosquera, Juan M; Sailer, Verena; Bareja, Rohan; Romanel, Alessandro; Gumpeni, Naveen; Sboner, Andrea; Dardenne, Etienne; Puca, Loredana; Prandi, Davide; Rubin, Mark A.; ... (2019). A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clinical cancer research, 25(1), pp. 43-51. American Association for Cancer Research 10.1158/1078-0432.CCR-18-1912
Wilkes, David C; Sailer, Verena; Xue, Hui; Cheng, Hongwei; Collins, Colin C; Gleave, Martin; Wang, Yuzhuo; Demichelis, Francesca; Beltran, Himisha; Rubin, Mark Andrew; Rickman, David S (2017). A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents. Cold Spring Harbor molecular case studies, 3(5) Cold Spring Harbor Laboratory Press 10.1101/mcs.a001487
Dhingra, Priyanka; Martinez-Fundichely, Alexander; Berger, Adeline; Huang, Franklin W; Forbes, Andre Neil; Liu, Eric Minwei; Liu, Deli; Sboner, Andrea; Tamayo, Pablo; Rickman, David S; Rubin, Mark Andrew; Khurana, Ekta (2017). Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network. Genome biology, 18(1), p. 141. BioMed Central Ltd. 10.1186/s13059-017-1266-3
Rickman, David S; Beltran, Himisha; Demichelis, Francesca; Rubin, Mark Andrew (2017). Biology and evolution of poorly differentiated neuroendocrine tumors. Nature medicine, 23(6), pp. 664-673. Nature Publishing Group 10.1038/nm.4341
